Search clinical trials for: Razoxane

Total 52 results

Kissei Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents

Extravasations of Anthracycline Anti-cancer Agents

Japan
University of Arkansas

Recruiting

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane (PHOENIX1)

Healthy

United States
Onxeo

Completed

Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

Anthracycline Extravasation

Denmark
Onxeo

Completed

A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Extravasation

Denmark, Germany, Italy, Netherlands, Poland
Medical City Children's Hospital
Mylan Pharmaceuticals Inc

Terminated

Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation

Heart Defects, Congenital

United States
University of Texas at Austin
Dell Children's Medical Center of Central Texas

Recruiting

Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery

Heart Defects, Congenital

United States
Thinq Pharma-CRO Pte. Ltd.
Unique Pharmaceuticals Ltd, India; THINQ Pharma CRO Ltd.

Unknown

A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis. (TPC)

Oropharyngeal Candidiasis

India
Fudan University

Terminated

Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer (cardioprotec)

Breast Cancer

China
Institut für Klinische Krebsforschung IKF GmbH...

Terminated

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

Advanced Soft Tissue Sarcoma

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Washington University School of Medicine

Completed

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma | Sarcoma, Soft Tissue | Leiomyosarcoma | Fibrosarcoma | Liposarcoma | Angiosarcoma | Malignant Peripheral Nerve Sheath Tumor | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Epithelioid Sarcoma | Myxofibrosarcoma

United States
PD Dr. Andrew Chan

Unknown

Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination (MSCardioPro)

Multiple Sclerosis

Germany
Dana-Farber Cancer Institute
Boston Children's Hospital

Terminated

Treatment of Childhood Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Puerto Rico, Canada
M.D. Anderson Cancer Center

Terminated

Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

Ewing's Sarcoma

United States
Fred Hutchinson Cancer Center
University of Washington

Completed

MMF for HIV Reservoir Reduction

Human Immunodeficiency Virus I Infection

United States
University of Chicago

Terminated

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

Osteosarcoma | Lung Metastases

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma

Sarcoma
Memorial Sloan Kettering Cancer Center

Recruiting

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Newly Diagnosed Ewing Sarcoma

United States
Dana-Farber Cancer Institute
Novartis

Completed

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (CRAD001NUS175T)

Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Childhood Chronic Myelogenous Leukemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic... and other conditions

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

Sarcoma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma

Sarcoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Sarcoma

United States
Princess Maxima Center for Pediatric Oncology
Daiichi Sankyo

Recruiting

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients (CHIP-AML22/Q)

Acute Myeloid Leukemia in Children

Netherlands
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

Sarcoma | Cardiac Toxicity

United States
National Cancer Institute (NCI)

Completed

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Cardiac Toxicity

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
UMC Utrecht; Amsterdam University Medical Centers; The Dutch Network for Cardiovascular...

Not yet recruiting

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (HO170DLBCL)

DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
M.D. Anderson Cancer Center

Terminated

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Osteosarcoma

United States
Jilin University

Unknown

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Antineoplastic Combined Chemotherapy Protocols

China
Children's Oncology Group
National Cancer Institute (NCI); Children's Cancer Group

Completed

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Lymphoma | Cardiac Toxicity

United States, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Sarcoma | Cardiac Toxicity

United States, Canada, Netherlands, Puerto Rico, Switzerland, Australia
Therapeutic Advances in Childhood Leukemia Consortium

Terminated

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Relapsed Acute Lymphoblastic Leukemia | Allergy to PEG e.Coli Asparaginase | Allergy to Native e.Coli Asparaginase

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Lymphoma | Cardiac Toxicity

United States, Canada, Switzerland
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Inflammatory Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Cardiac Toxicity

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Localized Extraskeletal Ewing Sarcoma | Peripheral Primitive Neuroectodermal Tumor of Bone | Peripheral Primitive Neuroectodermal Tumor of Soft Tissues

United States, Canada, Saudi Arabia, Australia, New Zealand, Puerto Rico
St. Jude Children's Research Hospital

Active, not recruiting

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Rhabdomyosarcoma

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Treatment of Acute Lymphoblastic Leukemia in Children

Leukemia | Drug/Agent Toxicity by Tissue/Organ

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

PRETEXT I Hepatoblastoma | PRETEXT II Hepatoblastoma | PRETEXT III Hepatoblastoma | PRETEXT IV Hepatoblastoma

United States, Canada, Puerto Rico, Australia, Japan, Brazil
Andrew E. Place, MD
University of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaborators

Recruiting

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditions

United States
St. Jude Children's Research Hospital

Active, not recruiting

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Dana-Farber Cancer Institute
Servier

Active, not recruiting

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Acute Lymphoblastic Leukemia, Pediatric

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma (T-Cell #4)

Lymphoma | Leukemia | Cardiac Toxicity
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Sarcoma

Canada, United States, Australia, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Recurrent Neuroblastoma | Childhood Solid Neoplasm | Recurrent Childhood Anaplastic Large Cell Lymphoma

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Australia, Canada, Puerto Rico
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

Central Nervous System Tumor, Pediatric

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
National Cancer Institute (NCI)

Not yet recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Puerto Rico

Search clinical trials for: Razoxane

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations